Monte Rosa Therapeutics, Inc. — Cyborg Score 7/10

Strong
Clinical-Stage Biotechnology / Precision Medicines

Strategic Profile

The company leverages its proprietary QuEEN discovery engine to enable target-centric MGD discovery and rational design of product candidates. Monte Rosa has established collaborations with major pharma partners including Novartis (with $120M upfront and up to $5.7B total deal value) and has secured $396.2M in cash as of Q3 2025.

Cyborg Score Rationale

MRT-2359 recently demonstrated 100% PSA and disease control rates in AR-mutant mCRPC Phase 1/2 data, indicating strong clinical efficacy. With $396.2M in cash and runway through 2028, plus a major Novartis collaboration generating meaningful revenue, the company has strong capital position and multiple clinical catalysts ahead including MRT-8102 Phase 1 readout in H1 2026.

Top Insights

  • Recent Phase 1/2 data for lead oncology candidate MRT-2359 showed 100% PSA response and disease control rates in AR-mutant metastatic castration-resistant prostate cancer
  • Novartis collaboration with $120M upfront and up to $5.7B in total deal value provides strong validation and revenue diversification
  • $396.2M in cash with runway through 2028 and multiple clinical readouts expected (MRT-8102 H1 2026, MRT-6160 Phase 2, updated MRT-2359 data by year-end 2025)
  • Broad pipeline spanning oncology, immunology, inflammation, cardiovascular, metabolic and genetic diseases provides multiple value inflection opportunities

Named Competitors

  • Protein Degradation Platform — PROTAC-based protein degradation
  • Protein Degradation Platform — Targeted protein degradation therapies
  • Protein Degradation Platform — E3 ligase-based protein degradation
  • Protein Degradation Platform — Protein degradation and epigenetics

Recent Developments

  • (February 2026) MRT-2359 demonstrates 100% PSA and disease control rates in AR-mutant mCRPC Phase 1/2 data
  • (Q3 2025) Novartis collaboration announced with $120M upfront and up to $5.7B total deal value; cash position $396.2M
  • (H1 2026) MRT-8102 Phase 1 initial readout expected on track

Open the full interactive Monte Rosa Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →